Delving into the Latest Updates on Shanghai Jingze Biotechnology Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Shanghai Jingze Biotechnology Co. Ltd. is a Chinese corporation that specializes in the research, development, and large-scale production of biopharmaceuticals.

Tags

Endocrinology and Metabolic Disease

Eye Diseases

Cardiovascular Diseases

Biological products

Biosimilar

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	4

Top 5 Drug Type	Count

Biosimilar	2
Biological products	2
Monoclonal antibody	1
Fusion protein	1
Enzyme	1

Top 5 Target	Count

PGF x VEGF-A	1
PLG(Plasminogen)	1

主要目的：比较在DME患者中玻璃体腔注射JZB05注射液和阿柏西普眼内注射溶液（EYLEA®）的临床有效性的相似性。临床有效性的相似性评价基于：给予JZB05和EYLEA®后第8周采用ETDRS视力表测得的最佳矫正视力（BCVA）较基线改善的字母数。

[Translation]

Primary objective: To compare the similarity of clinical effectiveness of intravitreal JZB05 injection and aflibercept intraocular injection solution (EYLEA®) in patients with DME. The similarity of clinical effectiveness was evaluated based on the number of letters of improvement in best corrected visual acuity (BCVA) measured by the ETDRS eye chart compared with baseline at week 8 after administration of JZB05 and EYLEA®.

Start Date09 Oct 2023

Sponsor / Collaborator

Shanghai Jingze Biotechnology Co., Ltd.

[+1]

CTR20241893 / RecruitingPhase 1

一项多中心、开放、单次给药剂量递增的重组人截短型纤溶酶（JZB32）注射液治疗症状性玻璃体黄斑粘连的 I 期临床试验

[Translation] A multicenter, open-label, single-dose escalation clinical trial of recombinant human truncated plasmin (JZB32) injection in the treatment of symptomatic vitreomacular adhesions

1．观察 JZB32 在症状性 VMA 受试者中单次给药的安全性； 2．探索 JZB32 在症状性 VMA 受试者中单次给药的最大耐受剂量（MTD）。

[Translation]

1. To observe the safety of a single dose of JZB32 in subjects with symptomatic VMA; 2. To explore the maximum tolerated dose (MTD) of a single dose of JZB32 in subjects with symptomatic VMA.

Start Date27 Oct 2022

Sponsor / Collaborator

Jiangsu Jingze Biomedical Co Ltd

[+2]

CTR20201777 / RecruitingPhase 1

一项单中心、开放、单次给药剂量递增的重组人截短型纤溶酶（JZB32）注射液治疗症状性玻璃体黄斑粘连的I期临床试验

[Translation] A single-center, open-label, single-dose escalation clinical trial of recombinant human truncated plasmin (JZB32) injection in the treatment of symptomatic vitreomacular adhesions

主要目的：观察JZB32在症状性VMA受试者中单次给药的安全性；次要目的：探索JZB32单次给药的药代动力学特征。

[Translation]

The primary objective was to observe the safety of a single dose of JZB32 in subjects with symptomatic VMA. The secondary objective was to explore the pharmacokinetic characteristics of a single dose of JZB32.

Start Date27 Oct 2022

Sponsor / Collaborator

Jiangsu Jingze Biomedical Co Ltd

[+2]

100 Clinical Results associated with Shanghai Jingze Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Jingze Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Shanghai Jingze Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Jingze Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

3

1

Phase 1 Clinical

Phase 3 Clinical

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Aflibercept biosimilar(Jingze Biotech) ( PGF x VEGF-A )	Diabetic macular oedema More	Phase 3
JZB-32 ( PLG )	Vitreomacular Adhesion More	Phase 1
JZB-60	Infertility, Female More	Preclinical
JZB-08	Diabetic Retinopathy More	Preclinical
JZB-36	Infertility, Female More	Preclinical